Andelyn Biosciences, Armatus Bio Partner for CMT1A Gene Therapy
Tuesday, January 16, 2024
Andelyn Biosciences, Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has formed a strategic partnership with Armatus Bio to expedite the manufacturing process for their gene therapy treatment targeting Charcot-Marie-Tooth Type 1A (CMT1A). CMT1A is a rare genetic neurological disease with no approved therapies, causing debilitating effects and potential fatal complications.
The collaboration aims to enhance program efficiency and accelerate the progression of this innovative precision approach to clinical studies. Armatus will leverage Andelyn's extensive expertise in adeno-associated virus (AAV) production and its proprietary suspension platform for various development activities, including plasmid manufacturing, viral vector toxicology, and GMP clinical manufacturing. This partnership reinforces the strong collaboration between the two organizations and brings hope to patients affected by neuromuscular diseases.
Both Andelyn Biosciences and Armatus Bio, situated in the thriving biotech hub of Columbus, Ohio, share a common belief in the continued advancement of human health through gene therapies.
Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, expressed appreciation for Armatus Bio's dedication to addressing the urgent unmet needs in CMT1A and praised their innovative therapeutic technology. Niloff looks forward to scaling up the process using Andelyn's program-specific, configurable suspension platform and expediting the therapy's entry into clinical trials with the utmost quality.
Brian Price, PhD, Chief Technical Officer of Armatus, highlighted Andelyn's demonstrated capabilities in manufacturing complex genetic medicines with high quality and consistency, emphasizing the critical role this will play in accelerating their development efforts. Price expressed anticipation for the collaboration with Andelyn as they work towards providing innovative solutions for the population eagerly awaiting treatment.
Drawing on its proven experience, Andelyn takes pride in offering exceptional development, plasmid production, and quality manufacturing at its three facilities in Columbus, Ohio. The company is dedicated to advancing client discoveries and manufacturing transformative cell and gene therapies for both rare and prevalent diseases.
Source: prnewswire.com
